Dec. 15, 2010 -- Fewer people are dying from cardiovascular disease and stroke since the late 1990s, but the economic toll remains high and the number of inpatient cardiovascular procedures performed to treat the illness has increased, according to a report.
Every year, the American Heart Association, in conjunction with the CDC, the National Institutes of Health, and other federal agencies, pools the latest data to see where the nation is in winning the war against cardiovascular disease, the number No. 1 in the U.S.
According to the American Heart Association, cardiovascular disease accounts for one death every 39 seconds in the U.S. There are more than 795,000 new or recurrent strokes every year. Coronary heart disease alone contributed to one in six deaths in the U.S. The cost of cardiovascular disease in both health expenditures and lost productivity stands at $286 billion; more than the cost of cancer and benign tumors, which was estimated to cost $228 billion.
Looking at data reported between 1997 and 2007, the most recent statistics available, investigators led by Veronique Roger, MD, MPH, chair of the health sciences research department at the Mayo Clinic in Rochester, Minn., found that the death rate from heart disease dropped by 27.8% and the stroke death rate declined by 44.8%. The findings appear online in Circulation: Journal of the American Heart Association.
“We’re seeing a decline in deaths for both, particularly for stroke,” Roger says. “We can attribute much of that to improved quality of care, with heart and stroke patients getting the care and treatment they need to live longer. But unfortunately the prevalence of these diseases and their risk factors are still high. We need to energize our commitment to strategies that can prevent disease in the first place.”
During the same period, the total number of inpatient cardiovascular operations and procedures increased 27%. The estimated total cost from heart disease and stroke in the United States for 2007 (including health expenditures and lost productivity) was $286 billion. That’s higher than any other diagnostic group. In 2008, the estimated cost of all cancer and benign tumors was $228 billion, according to the update.